Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study

IMPORTANCE: Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain metastases. Several studies have shown that adding chemotherapy to EGFR-TKIs could improve progression-free survival (PFS) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xue, Li, Meichen, Wu, Guowu, Feng, Weineng, Su, Jin, Jiang, Honghua, Jiang, Guanming, Chen, Jing, Zhang, Baishen, You, Zhixuan, Liu, Qing, Chen, Likun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909498/
https://www.ncbi.nlm.nih.gov/pubmed/36753281
http://dx.doi.org/10.1001/jamanetworkopen.2022.55050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909498/
https://www.ncbi.nlm.nih.gov/pubmed/36753281
http://dx.doi.org/10.1001/jamanetworkopen.2022.55050

Ejemplares similares